Rituxan user dies of brain infection
From Times Wire Services
Federal regulators said one case of a deadly brain infection has been reported in a patient taking Genentech Inc. and Biogen Idec Inc.’s popular arthritis and cancer drug Rituxan.
The Food and Drug Administration said the woman died of the rare viral infection more than a year and a half after discontinuing the drug, which Genentech and Biogen Idec co-market in the U.S.
The FDA said the case was the first reported in a patient taking the drug for arthritis.
